Median overall survival was 14.4 months in the zolbetuximab arm vs 12.2 months in the CAPOX-only group (HR, 0.771), and median progression-free survival was 8.2 months in the zolbetuximab arm vs 6 ...

Errata in: Lancet 2023;402(10398):290; Lancet 2024;403(10421):30.3 Shah MA, Shitara K, Ajani JA, et al. Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction ...

Previous studies have found that the combination of Zolbetuximab+CAPOX in CLDN18.2 positive patients, regardless of the PD-L1 status, leads to an improvement in PFS from 6.80 to 8.21 months (HR ...

In GLOW, treatment with zolbetuximab plus CAPOX statistically significantly improved progression free survival (PFS) (hazard ratio [HR], 0.687; [95% CI, 0.544-0.866]; ...

Updated results with longer follow-up reveal confirmed ORR of 68% and median PFS of 14.2 months in patients with CLDN18.2 high or medium expression, known PD-L1 CPS (n=66). PRINCETON, N.J. and ...

As of the data cut-off date (October 2022), treatment with zolbetuximab in combination with CAPOX showed a statistically significant benefit with a 31% reduction in the risk of a patient experiencing ...

Transcenta Holding Limited ("Transcenta") (HKEX: 06628), a global clinical stage biopharmaceutical company with fully-integrated capabilities in discovery, research, development and manufacturing of ...